GENEVAX (Hebei) Biotechnology Co., Ltd.

To evaluate the safety and immunogenicity of recombinant herpes zoster vaccine in people aged 40 years and above.

This trial aims to evaluate the safety and immunogenicity of two doses of recombinant herpes zoster vaccine in healthy people aged 40 years and above, and to explore the immunization schedule (0, 2 months and 0, 1 month immunization schedule).

The primary objective is to evaluate the safety of recombinant respiratory syncytial virus vaccine (CHO cells) in people aged 18-59 years and people aged ≥60 years; the secondary objective is to evaluate the humoral immune response, immune persistence and cellular immune response; the exploratory objective is to evaluate the level of anti-Ferritin protein antibodies after vaccination.